Table 1. Baseline patient demographics and characteristics.
| ABC/3TC+ATV (N = 199) | TDF/FTC+ATV/r (N = 97) | |
| Median age, years (range) | 44 (21–66) | 42 (20–68) |
| Male, n (%) | 155 (78) | 79 (81) |
| Race, n (%) | ||
| African American/African Heritage | 65 (33) | 37 (38) |
| White/Caucasian/European Heritage | 122 (61) | 55 (57) |
| Other | 12 (6) | 5 (5) |
| Hispanic or Latino Ethnicity, n (%) | 51 (26) | 26 (27) |
| Median plasma HIV-1 RNA, log10 copies/mL | 1.59 | 1.59 |
| <50 copies/mL, n (%) | 192 (96) | 93 (96) |
| 50 to 74 copies/mL, n (%) | 2 (1) | 2 (2) |
| ≥75 copies/mL, n (%) | 5 (3) | 2 (2) |
| Median CD4+ cell count, cells/µL (range) | 492 (77–1196) | 480 (108–1479) |
| <200 cells/µL, n (%) | 14 (7) | 6 (6) |
| CDC classification for HIV infection, n (%) | ||
| Category A | 136 (68) | 67 (69) |
| Category B | 26 (13) | 13 (13) |
| Category C | 37 (19) | 17 (18) |
| Hepatitis C coinfection, n (%) | 18 (9) | 8 (8) |
| Median time on prior ART, days (range) | 978 (177–4830) | 1106 (199–7078) |
ART = antiretroviral therapy.